Hims & Hers Health (HIMS) Cash from Investing Activities (2019 - 2026)
Hims & Hers Health (HIMS) reported Cash from Investing Activities of -$15.4 million for Q1 2026, up 52.9% on a YoY basis from -$10.1 million in Q1 2025, and up 81.54% sequentially from -$83.7 million in Q4 2025.
Hims & Hers Health (HIMS) Cash from Investing Activities (2019 - 2026) Analysis & Trends
Hims & Hers Health (HIMS) has 8 years of Cash from Investing Activities data on file, last reported at -$15.4 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities rose 52.9% year-over-year to -$15.4 million; the trailing twelve-month figure through Mar 2026 stood at -$1.0 billion (down 1452.89% YoY), and the FY2025 full-year result was -$1.0 billion, down 5280.92% from the prior year.
- Cash from Investing Activities climbed to -$15.4 million in Q1 2026, from -$83.7 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $20.7 million in Q4 2023 to a low of -$887.4 million in Q3 2025.
- A 5-year average of -$61.0 million and a median of -$4.5 million in 2024 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities jumped 417.09% in 2024 and plunged 8421.2% in 2025, its largest moves.
- Tracing HIMS's Cash from Investing Activities over 5 years: stood at $6.0 million in 2022, then surged by 244.74% to $20.7 million in 2023, then plunged by 183.14% to -$17.2 million in 2024, then sank by 386.32% to -$83.7 million in 2025, then jumped by 81.54% to -$15.4 million in 2026.
- Business Quant data shows HIMS's Cash from Investing Activities at -$15.4 million in Q1 2026, -$83.7 million in Q4 2025, and -$887.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.06 Bn | 87.19 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.51 Bn | 30.57 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 23.18 Bn | 21.03 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.48 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.75 Bn | 16.43 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.63 Bn | 12.21 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Hims & Hers Health | 6.77 Bn | 6.01 Bn | 396.79 Mn | -15.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.45 Mn |
| Mar 31, 2026 | -15.45 Mn |
| Dec 31, 2025 | -83.68 Mn |
| Dec 31, 2025 | -83.68 Mn |
| Sep 30, 2025 | -887.40 Mn |
| Sep 30, 2025 | -887.40 Mn |
| Jun 30, 2025 | -21.09 Mn |
| Jun 30, 2025 | -21.09 Mn |
| Mar 31, 2025 | -32.80 Mn |
| Mar 31, 2025 | -32.80 Mn |
| Dec 31, 2024 | -17.21 Mn |
| Dec 31, 2024 | -17.21 Mn |
| Sep 30, 2024 | -10.41 Mn |
| Sep 30, 2024 | -10.41 Mn |
| Jun 30, 2024 | -4.47 Mn |
| Jun 30, 2024 | -4.47 Mn |
| Mar 31, 2024 | 13.04 Mn |
| Mar 31, 2024 | 13.04 Mn |
| Dec 31, 2023 | 20.70 Mn |
| Dec 31, 2023 | 20.70 Mn |